Page 6 - Flipbook

Disclosures

• All biases in my interpretations are mine.

• My institution has a commercial interest in abiraterone, PARP inhibition in DNA

repair defective cancers and PI3K/AKT pathway inhibitors (no personal income)

• I have served on advisory boards for many companies including Astra Zeneca,

Astellas, Bayer, Boehringer Ingelheim, Genentech/Roche, Genmab, GSK, Janssen,

Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer,

Sanofi Aventis, Taiho.

• My institution has received funding or other support for my research work from

AZ, Astellas, Bayer, Genentech, GSK, Janssen, Merck Serono, MSD,

Menarini/Silicon Biosystems, Orion, Sanofi Aventis, Taiho.

• I have been the CI/PI of many industry sponsored clinical trials